Results 111 to 120 of about 160,542 (279)

Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience

Advances in Radiation Oncology
Purpose: The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiation therapy (RT), and adjuvant pembrolizumab.
Thais Tison, MD, Pierre Loap, MD, Emilie Arnaud, MD, Kim Cao, MD, Solene Bringer, MD, Manon Kissel, MD, Safia Maaradji, MD, Juliette Mainguene, MD, Jean-Yves Pierga, MD, PhD, Florence Lerebours, MD, Anne Vincent-Salomon, MD, PhD, Mariana Mirabelle, MD, Francois-Clement Bidard, MD, PhD, Delphine Loirat, MD, PhD, Youlia M. Kirova, MD   +14 more
doaj   +1 more source

Visualization of Scattered Tumor Regression Following Neoadjuvant Chemoimmunotherapy With a Novel Intraoperative PET/CT Scanner

Head &Neck, EarlyView.
ABSTRACT Background Neoadjuvant chemoimmunotherapy is being explored in locally advanced head and neck squamous cell carcinoma (HNSCC), yet the spatial patterns of pathologic response and clinical implications remain poorly characterized. Methods A 79‐year‐old female with recurrent left oral tongue SCC (PD‐L122C3 Combined Positive Score 90) who ...
Andreja Radevic, Joaquin Austerlitz, Ashtyn McAdoo, Kyrionna Golliday, Takeshi Takahashi, Mitra Mehrad, Adam J. Rosenberg, Barbara A. Murphy, Eben Rosenthal, Michael C. Topf   +9 more
wiley   +1 more source

Pembrolizumab in HER2-Positive Gastric Cancer

Pembrolizumab in HER2-Positive Gastric Cancer The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy ...
Lowery, Maeve, Kawazoe, Akihito, Mahave, Mauricio, Tang, Yong, Shih, Chie-Schin, Ostapenko, Yuriy, Tabernero, Josep, Lonardi, Sara, Xu, Linzhi, Luo, Suxia, Janjigian, Yelena Y., Bhagia, Pooja, Yanez, Patricio, Van Cutsem, Eric, Sharan, Kanu P., Xu, Jianming, Bai, Yuxian, Shitara, Kohei, Bilici, Mehmet, Rha, Sun Young, Monteiro, Maria M. F., Shen, Lin, Chung, Hyun Cheol, Metges, Jean Phillipe, Qin, Shukui, Wyrwicz, Lucjan S.   +25 more
core   +1 more source

Clinicogenomic Features and Outcomes of Adenoid Cystic Carcinoma With Central Nervous System Metastases: A Single‐Institution Cohort Study

Head &Neck, EarlyView.
ABSTRACT Background Adenoid cystic carcinoma (ACC) is a rare malignancy with a propensity for perineural invasion and hematogenous spread. Central nervous system (CNS) involvement is uncommon, and detailed clinical and genomic data on this aspect of the disease remain limited.
Omar Elghawy, Jack Stylli, Martin Kurian, Eitan Halper‐Stromberg, Aditi Singh, Christopher D'Avella, Lee Hartner, Roger B. Cohen   +7 more
wiley   +1 more source

Non‐Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy?

Head &Neck, EarlyView.
ABSTRACT Background In patients with locally advanced, non‐metastatic oropharyngeal squamous cell carcinoma (OPSCC), surgery‐based and nonsurgical treatment approaches have not been adequately compared in randomized Phase III clinical trials. Current clinical guidelines recommend various surgical and nonsurgical strategies across disease stages for ...
Primož Strojan, Avraham Eisbruch, June Corry, Sandra Nuyts, Pim de Graaf, Luiz P. Kowalski, Jonathan J. Beitler, Sweet Ping Ng, William M. Mendenhall, M. P. Sreeram, Karthik N. Rao, Anna Luíza Damaceno Araújo, Alfio Ferlito   +12 more
wiley   +1 more source

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

BMC Cancer
Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective inhibitor ...
Primo N. Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo Perini, Toni K. Choueiri, Robert J. Motzer   +19 more
doaj   +1 more source

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer

Journal for ImmunoTherapy of Cancer
Intravenous immune checkpoint inhibition achieves a 40% 3-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
Joshua J Meeks, Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy   +4 more
doaj   +1 more source

Early Feasibility of Registration of Micro‐PET/CT Scans to Annotated 3D Specimen Models

Head &Neck, EarlyView.
ABSTRACT Background Intraoperative 18F‐fluorodeoxyglucose (18F‐FDG) micro‐positron emission tomography/computed tomography (micro‐PET/CT) is an emerging modality for margin assessment. Prior to clinical use, micro‐PET/CT margin distances must be correlated with gold‐standard histopathology.
Joaquin Austerlitz, Andreja Radevic, Ashtyn McAdoo, Kyrionna Golliday, Cheng Ye, Daniel Fabbri, Adam J. Rosenberg, Marcus Balanky, Anas Alabkaa, Kim A. Ely, Mitra Mehrad, Spencer Roark, Eben Rosenthal, Michael C. Topf   +13 more
wiley   +1 more source

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

BMC Cancer
Background Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly selective inhibitor of IDO1.
Irfan Cicin, Elizabeth R. Plimack, Howard Gurney, Raya Leibowitz, Boris Y. Alekseev, Francis X. Parnis, Avivit Peer, Andrea Necchi, Joaquim Bellmunt, Hiroyuki Nishiyama, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Thomas Powles, Cora N. Sternberg   +15 more
doaj   +1 more source

Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review

Head &Neck, EarlyView.
ABSTRACT Objective To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. Summary Background Data Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients ...
Nicholas Brian Shannon, Bruce Ashford
wiley   +1 more source